j31

J-31 is an inactive conformation inhibitor of ITK.

SJ3149 is a selective and powerful CK1α protein degrader, effective both in vitro and in vivo, and demonstrates antitumor activity [1].

Anti-RatCD28Antibody (JJ319) is a mouse-derived IgG1, κ antibody inhibitor targeting rat CD28.

Anti-RatCD28Antibody (JJ316) is a mouse-derived IgG1 kappa antibody targeting CD28. The isotype control for Anti-RatCD28Antibody (JJ316) is MouseIgG1 kappa, Isotype Control.

Bavisant (JNJ-31001074) is a selective and orally active Human H3 receptor antagonist. Bavisant can be used in research on mechanisms of action, involving wakefulness and cognition and the treatment for ADHD.

Bavisant dihydrochloride hydrate (JNJ31001074AAC) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action related to wakefulness and cognition, and it has potential as a treatment for ADHD. In a clinical trial, the mean change from baseline in the total ADHD-RS-IV score at day 42 was -8.8 in the placebo group versus -9.3, -11.2, and -12.2 in the bavisant 1 mg/day, 3 mg/day, and 10 mg/day groups, respectively; however, the change in the 10 mg/day group was not statistically superior to placebo (p=0.161). Statistical comparisons of the 1 mg/day and 3 mg/day groups with placebo based on a step-down closed testing procedure were not performed. Bavisant has completed a phase II ADHD trial, but no results have been reported [1]. Clinical trial: A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers. Phase 2. IC50 Value: Target: H3 receptor in vitro.

(R)-JNJ-31020028 is a high-affinity, selective brain-penetrant antagonist of the neuropeptide Y Y2 receptor, with pIC50 values of 8.07, 8.22, and 8.21 for human, rat, and mouse Y2 receptors, respectively.

JNJ-31020028 is a selective brain penetrant antagonist of neuropeptide Y2 receptor with high affinity(pIC50=8.07, human; pIC50=8.22, rat); it exhibits >100-fold selectivity for Y2 versus human Y1/Y4/Y5 receptors.